Kornimate/medical-research-clean huggingface dataset:
norwegian cardio-respiratory arrest study

Conditions: Cardiac Arrest; Respiratory Arrest; Coma

Summary: the purpose of this study is to evaluate the use of combined clinical-neurological, neurophysiologic, neuroradiological and biochemical markers in prognostication after cardio- and/or respiratory arrest.

cardiac arrest (ca) is a leading cause of death, affecting about 700.000 individuals each year in europe. acute myocardial infarction (ami) and primary arrhythmia are the most common causes of ca, whereas respiratory arrest is a leading cause of secondary ca. patients who have undergone cardiopulmonary resuscitation (cpr) often remain unconscious after hospital admission, either as a result of severe permanent brain damage or a merely reversible metabolic disturbance due to post-ischemic global reperfusion. early prediction of neurological and cardiac outcome remains a difficult task for physicians. the decision to continue, limit or terminate intensive care therapy carries huge ethical and socioeconomic implications. optimal emergency cardiovascular care, cardiac failure therapy and ca prevention after hospitalisation also remain difficult issues for cardiologists and intensive care doctors. in this prospective study running from 2010, both prognostication and in-hospital treatment are studied in a population of 261 patients with out-of-hospital cardio-respiratory arrest. the use of combined clinical-neurological, neurophysiologic, neuroradiological and biochemical markers is studied to asses whether a poor neurological outcome (cerebral performance category 3-5) can be predicted with \~100% specificity and a sensitivity that is sufficient for practical clinical use. pre-disposing and triggering causes of cardiorespiratory arrest are also registered. patients with pre-existing conditions coherent with prophylactic icd implementation under current international guidelines will be identified, in order to assess and further improve icd-prophylactic treatment in norway. the potential benefit of invasive picco-monitoring after ca will also be evaluated, and a subproject identifying biomarkers for ca risk has been established. nirs (near-infrared spectroscopy) will also be used to register cerebral oxygenation in the early days after cardiorespiratory arrest. the overall aim of the norcast study is to provide physicians with better tools to asses cardiac and neurological outcome as early and as accurate as possible. all alive study patients are invited to long-term follow-up consultaions after 6 months, after 4 years, and after 10 years. the consultations will include study examinations, structured interviews and questionnaires. questionnaires will also be used for next of kin.

Eligibility criteria:
inclusion criteria: * prehospital cardial resuscitation * prehospital pulmonary resuscitation * rosc before/on admission to hospital * \> 18 years of age exclusion criteria: * death on admission to hospital * arrhythmic cardiac arrest with als \< 5min and spontaneous awakening * in-hospital cardiac arrest * trauma patients
evaluation of the diagnostic and prognostic role of pet (pet/ct and pet/mri) in neuroendocrin tumors.

Conditions: Neuroendocrine Tumors

Summary: neuroendocrine tumors (nets) constitute approximately 0.5% of malignancies. to date, diagnosis at an increasingly early stage of the disease is possible thanks to recent technological advances in biomedical imaging. in particular, the traditional work-up for these pathologies includes endoscopy, magnetic resonance imaging (mri) and computed tomography (ct). furthermore, the integrated positron emission tomography methods (pet/ct and pet/mri) are innovative molecular imaging techniques and represent a continually expanding field of research in the oncology setting. in particular, pet is taking on an increasingly relevant role for the study of neuroendocrine tumors, also thanks to the introduction of increasingly accurate radiopharmaceuticals (targeted towards somatostatin receptors), thus opening the way to new possibilities for the diagnosis andcharacterization of these tumors, is in the staging and restaging phase .


Eligibility criteria:
inclusion criteria: * adult patients affected by neuroendocrine tumors; patients who have performed at least one pet study with 18f-fdg and/or 68ga- dotatoc for the staging or diagnosis of their pathology. exclusion criteria: * patients \< 18 years old; * lack of availability of clinical data and pet imaging useful for analyses.
international covid-19 clinical evaluation registry -2 (hope-2)

Conditions: Covid19

Summary: purpose. the main objective of the present study is to carefully characterize the clinical profile of individuals with lasting sequelae after a covid-19 admission. as secondary objectives, the analysis of the risk-adjusted influence of covid-19 severity, previous comorbidities and management of patients discharged after covid-19 will be performed. design and statistical analysis cross-sectional and prospective registry, a real life "all comers" type, with voluntary participation, without specific funding or conflicts of interest. it is a study initiated by researcher that will have advanced statistical support from the imas foundation (institute for the improvement of health care, madrid, spain) and the cardiovascular research foundation (fic, madrid, spain). international level. participants protocol. the study has been approved by hospital clinico san carlos ethic´s committee (21/128-e) and the institutional board of each participating center. the present study proposes the continuation in time of the work previously carried out in the hope registry. it proposes to select all the patients attended in any health center (with in hospital beds), who have been discharged or have died up to 31st august 2020. all will be considered eligible with a positive covid-19 test (any type) or if their attending physicians consider them highly likely to have presented the infection. given the anonymous characteristics of the registry and the health alarm situation generated by the virus, in principle, it is not considered necessary to provide written informed consent.


Eligibility criteria:
inclusion criteria: * patients discharged (deceased or alive) from any hospital center with a confirmed diagnosis. exclusion criteria: * there are no exclusion criteria, except for the patient's explicit refusal to participate.
suicide risk prediction in cancer patients

Conditions: Cancer

Summary: previous studies have found that the suicide risk of cancer patients is influenced by socioeconomic factors, clinical characteristics, and environmental factors. but prediction model with multiple predictors for suicide risk in cancer patients is limited. the aim of this study is to assess the association of socioeconomic factors, clinical characteristics and meteorological factors with cancer patients' suicide, based on retrospective cohorts, and to establish a suicide risk prediction model with multiple predictors for cancer patients.

cancer is a serious public health concern, with almost 10 million people dying from cancer in 2020. previous studies have reported that cancer patients are more likely to die by suicide than the general public, especially in the six months to one year following cancer diagnosis. since suicide is a result of the interaction of various factors such as socioeconomic factors, clinical characteristics, and environmental factors, it is necessary to construct a multivariate prediction model to predict the suicide risk in cancer patients. a retrospective cohort of cancer patients based on the surveillance, epidemiology, and end results (seer) program database was used to assess the association of socioeconomic factors, clinical characteristics and meteorological factors with cancer patients' suicide, and to establish prediction model with multiple predictors for cancer patients. another retrospective cohort conducted from shandong multi-center healthcare big data platform (smchbdp) was used to verify the predictive ability and generalization ability of the prediction model.

Eligibility criteria:
inclusion criteria: 1. cancer patients in seer database and smchbdp exclusion criteria: 1. no certain cause of death 2. missing area code 3. lost to follow-up

Keywords: cancer patients suicide risk prediction model meteorological factors
computer games to prevent mild cognitive impairment and dementia

Conditions: Mild Cognitive Impairment

Summary: the aim of the study is to show that regular playing with the logic games developed in the framework of the m3w (mental wellness toolset) project (https://m3w-project.eu/) can prevent mild cognitive impairment (mci) and dementia. the secondary aim of the study is to find correlations between the results of the games and the standard assessments for dementia and mci screening such as the rey verbal learning test.


Eligibility criteria:
inclusion criteria: * both gender * older than 50 years of age exclusion criteria: * subjects with history of head trauma, epilepsy or stroke. * diagnosis of schizophrenia * acute manic episode
study to assess the safety and efficacy of onzetra® xsail® for the acute treatment of episodic migraine with or without aura in adolescents

Conditions: Acute Migraine With or Without Aura

Summary: this study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (avp-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.

this is a phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating avp-825 for the acute treatment of migraine with or without aura in adolescent subjects (12 to 17 years old).

Eligibility criteria:
inclusion criteria: * male and female participants 12 to 17 years (inclusive) of age at the time of informed consent * have a diagnosis of episodic migraine with or without aura according to international classification of headache disorders-third edition, beta version (ichd-iiib, 1.2.1 or 1.1) criteria, for at least 1 year prior to the screening/enrollment visit * experienced migraine attacks of moderate-to-severe intensity and typically lasting ≥ 3 hours untreated, occurring at a frequency of ≥ 2 to ≤ 14 attacks per month for the past 6 months prior to the screening/enrollment visit * participant's parent or legal guardian must be willing to sign a copy of the informed consent form as well as documentation for written authorization for use and release of health and research study information, after the nature and risks of study participation have been fully explained. participants must be willing to provide informed assent. exclusion criteria: * participants with ≥ 15 headache days per month in total (migraine, probable migraine, or tension-type) * participants with the following headache types: retinal (ichd-iiib, 1.2.4), with brainstem aura (ichd-iiib, 1.2.2), hemiplegic (ichd-iiib, 1.2.3), status migrainosus (ichd-iiib, 1.4.1), other forms of complicated migraine, or secondary headaches * participants who have not responded to an adequate dose and appropriate duration of treatment with 2 or more triptans * participants with known nasal obstruction, current uncontrolled nasopharyngeal illness, or known velum insufficiency (i.e., a cleft palate and/or structural abnormalities in the soft palate and nasopharynx) that may interfere with the proper use of study medication * participants whose conditions in the investigator's opinion may put the participant at significant safety risk or confound the study results. this includes participants who in the investigator's opinion should not be enrolled in the study due to the risks described in the warnings and precautions or contraindications sections of the onzetra xsail prescribing information.

Keywords: acute migraine aura sumatriptan nasal powder avp-825 adolescents
clinical investigation of the medtronic concerto™ device

Conditions: Congestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial Fibrillation

Summary: heart failure is a progressive disease that decreases the pumping action of the heart. this may cause a backup of fluid in the heart and may result in heart beat changes. when there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. in certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy may be prescribed. people who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (icd). atrial tachyarrhythmia (at) is the name for rapid beats in the upper chambers of the heart. people with at may experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue or weakness. the purpose of this study is to study an investigational implantable device containing cardiac resynchronization therapy (crt) and implantable cardioverter defibrillator (icd) therapies (crt+icd device) in subjects who are at significant risk of developing atrial tachyarrhythmias.


Eligibility criteria:
inclusion criteria: * subjects who require the implantation of an implantable cardioverter defibrillator * subjects who have heart failure that severely limits daily activities (nyha class iii) or subjects who have severe heart failure and should always be resting (nyha class iv) * subjects with reduced heart pumping function (left ventricular ejection fraction ≤ 35%) exclusion criteria: * subjects who have constant atrial fibrillation (top chambers of the heart beat too fast continuously) * subjects who are post-heart transplant

Keywords: congestive heart failure, atrial arrhythmia, cardiac resynchronization therapy, implantable cardioverter defibrillator
platelet function in diabetic patients with and without renal impairment, and the effects of lipid lowering treatment

Conditions: Diabetes Mellitus; Impaired Renal Function

Summary: the purpose of this study is compare the effects of simvastatin+ezetimibe with those of simvastatin alone on platelet activity, platelet-leukocyte interactions and inflammatory variables in diabetic patients with or without impaired renal function.

a detailed study protocol is available.

Eligibility criteria:
inclusion criteria: * diabetes mellitus type 1 or type 2 * with or without established microalbuminuria (albumin-to-creatinine ratio (acr)2,5-25 mg/mmol for men, and 3,5-25 mg/mmol for women, according to ish and esc recommended criteria) * glomerular filtration rate (gfr) between 15-60 ml/min/1.73m2 (measured the last 6 months) or gfr \>75ml/min/1.73m2. the abbreviated modification of diet in renal disease (mdrd) equation will be used to calculate gfr. * age 18-80 years exclusion criteria: * definite history of myocardial infarction, coronary revascularisation procedure or stroke. (i.e, a strong clinical indication for statin treatment) * functioning renal transplant, or living donor-related transplant planned. * patients on dialysis. * poor metabolic control, i.e hba1c \> 9% * definite history of chronic liver disease, or abnormal liver function (i.e alt \>1,5 x uln or, if alt not available, ast \> 1,5 x uln). * evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or ck\>3 x uln; * definite previous adverse reaction to a statin or to ezetimibe * definite previous adverse reaction to acetylsalicylic acid. * definite previous adverse reaction to an ace-inhibitor. * need for concomitant treatment with a strong inhibitor of cyp3a4, such as itrokonazole, ketokonazole, erythromycin, clarithromycin, hiv-protease inhibitors or nefazodone (i.e. agents that may markedly elevate simvastatin levels).
comparing semaglutide administered subcutaneously once daily to semaglutide administered subcutaneously once weekly

Conditions: Diabetes; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to compare the steady-state exposure of semaglutide administered subcutaneously once daily to semaglutide administered subcutaneously once weekly in healthy subjects.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-55 years (both inclusive) at the time of signing informed consent * considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, ecg and clinical laboratory tests performed during the screeningvisit, as judged by the investigator * body mass index (bmi) between 20.0 and 29.9 kg/m\^2 (both inclusive) * hba1c (glycosylated haemoglobin) below 6.5% exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method throughout the trial including the 5 weeks follow-up period (adequate contraceptive measures as required by local regulation or practice) * any disorder which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol * history of pancreatitis (acute or chronic) * screening calcitonin equal or above 50 ng/l * family or personal history of multiple endocrine neoplasia type 2 (men2) or medullary thyroid carcinoma (mtc)
non-interventional study with novocart® inject in the reconstruction of the knee cartilage defects

Conditions: Cartilage Disease

Summary: retrospective non-interventional study to evaluate safety and efficacy of novocart® inject in patients with full-thickness cartilage defects in the knee joint.

retrospective and multicenter non-interventional study to evaluate safety and efficacy of novocart® inject in patients with localized full-thickness cartilage defects in the knee joint. safety: measuring the number of adverse drug reactions/serious adverse drug reactions since treatment and up to the present time. efficacy: evaluate symptoms and functional status at the present time using ikdc 2000 (international knee documentation committee) and koos (knee injury osteoarthritis outcome score).

Eligibility criteria:
inclusion criteria: * male and female patients * juvenile patients with closed epiphysial plate * insulated full-thickness cartilage damage of the knee joint, icrs (international cartilage repair society) grade 3-4 * defect size ≥ 2.5 and ≤ 10 cm2 * intact or reconstructed bony subchondral plate * in the case of deep bony substance defects, additional bony reconstruction is needed exclusion criteria: * radiographic signs of osteoarthritis of kellgren and lawrence \> 2 * joint stiffness * arthrofibrosis * malalignment in the knee (valgus- or varus deformity) \> 3° (correction contemporary to the act) * insufficient reconstructed ligaments (correction contemporary to the act) * defective position patella (correction contemporary to the act) * sled prosthesis implants or carbon pin * inflammatory joint diseases (f.e. rheumatoid arthritis) * corresponding cartilage defects ("kissing lesions") * more than two independent cartilage defects in one knee * primary cartilage reconstructive treatment in children and juvenile with open epiphysial plate * diffuse chondromalacia * congenital or gained deformity of patella

Keywords: cartilage defect knee act (autologous chondrocyte implantation) novocart® inject
arrhythmia detection in obstructive sleep apnea (adios)

Conditions: Atrial Fibrillation; Arrhythmia; Stroke, Cardiovascular

Summary: the purpose of this research study is to learn about arrhythmia detection in obstructive sleep apnea (osa). for several years patients with osa have an increased likelihood of having irregular heartbeats. this study will determine how often patients with osa have irregular heartbeats. this study will also define which osa patients are most likely to have irregular heartbeats. the participant is being asked to be in the study because the participant has been diagnosed with obstructive sleep apnea (osa).


Eligibility criteria:
inclusion criteria: 1. diagnosis of osa within the last 12 months 2. no previous diagnosis of atrial fibrillation 3. able and willing to follow-up as an outpatient 4. age 40-85 years exclusion criteria: 1. life expectancy \< 2 years 2. dementia or other neurologic condition which would make outpatient follow-up difficult 3. chads score \<2 4. alcohol or drug abuse which would interfere with outpatient follow-up 5. severe congestive heart failure (nyha class 3 or 4) or use of left ventricular assist device. 6. current dialysis treatment or planned treatment within 12 months 7. known bleeding disorder or prothrombin time \>15 seconds 8. mechanical heart valve requiring anticoagulation 9. moderate to severe mitral stenosis or regurgitation 10. prior clinical diagnosis of ischemic stroke (radiologic infarcts are not excluded) 11. chronic obstructive pulmonary disease with oxygen dependence 12. pregnant patients or patients that plan to become pregnant within the course of the study\*. 13. patients with anticipated need for a pacemaker during the course of the study \*if any patients become pregnant during the course of the study, pregnancy outcomes will not be followed

Keywords: sleep apnea arrhythmia detection
sleep apnoea breathing record exploratory study (sabres)

Conditions: Sleep Apnea

Summary: during sleep, many people have times when they breathe shallowly or completely stop. if a person stops breathing for more than 10 seconds, this is called an 'apnoea'. if shallow breathing lasts for more than 10 seconds, it is called a 'hypopnoea'. if a person has these events frequently, it disrupts their sleep and they do not awake refreshed. it can also put strain on the heart, leading to cardiovascular conditions. these sleep disorders, usually called 'sleep apnoea', can be treated for most people using 'continuous positive airways pressure', cpap. current tests for sleep apnoea, usually used at home, are expensive, complicated for patients to use and do not monitor actual breathing. the new test, called apne-scan, is very simple and will cost less than the standard tests. it just requires the user to wear a mask, similar to ones used for cpap treatment, overnight and then send the mask off for data analysis. the apne-scan mask, developed with taxpayer funding, is fitted with a pressure sensor to monitor actual breathing. people between the ages of 18-70 who have been referred to the sleep clinic at royal stoke university hospital are eligible to participate in this exploratory study. they will wear the apne-scan mask at the same time as their standard overnight sleep apnoea test. the breathing data collected by apne-scan will be analysed by apnea-tech limited, the device manufacturers, so that it can be compared to the data captured by the standard sleep apnoea test.


Eligibility criteria:
inclusion criteria: * have been referred by a clinician to the sleep clinic for diagnosis of a sleep disorder, possibly sleep apnoea. * be about to be screened for possible sleep apnoea using a standard sleep apnoea test device. * be between the ages of 18 and 75 and have provided informed consent for the study exclusion criteria: * have not been referred by a clinician to a sleep clinic for diagnostic tests for sleep disorders other than for possible sleep apnoea. * cannot tolerate wearing a mask overnight. * cannot remove a mask should they become distressed. * are not capable of understanding the english language version of apne-scan's instructions for use (ifu). * are under the age of 18 years old or over the age of 75 years old. * are not capable of giving informed consent